Recently it was announced that the BLA (biologics license application) for a product purported as biosimilar to branded trastuzumab, and indicated to treat certain HER2-positive breast cancers, was accepted by the FDA. Mylan and Biocon submitted the BLA for MYL-1401O; its acceptance by the FDA is an important step forward for providing U.S. patients with this type of breast cancer …
As a pharmaceutical manufacturer, you may think coding and marking systems are error-prone and at many times difficult to manage. Whether for printing barcodes, 2D codes, expiration dates, lot codes, Data Matrix codes or other data, the pharmaceutical industry is one in which reliable coding is a must, not an option. Counterfeiting has been a huge concern in the pharmaceutical …
Recently it was revealed in a news release that Cumberland, MD based FOSRx (Factor One Source Pharmacy) would acquire F.A.S.T. (Fast Access Specialty Therapeutics) based in Metairie, LA through a combination of cash and stock. FOSRx, or Factor Once Source Pharmacy serves patients across the U.S., providing specialty prescriptions for those requiring specialized management of medications for chronic medical conditions. …
Recently in pharma news, Zydus Cadila announced the Ahmadabad-based company has acquired six brands from Merck India, also referred to as MSD outside of the U.S. and Canada, through its wholly-owned subsidiary Zydus Healthcare Ltd. News reports do not indicate how much Zydus Cadila paid for these brands, which fall in the wound management therapy, cardiovascular, and men and women’s …
Recently it was announced that Fluor Corporation of Irving, TX landed a $1.2 billion contract to design and build the $2 billion manufacturing facility for Novo Nordisk‘s diabetes API (Active Pharmaceutical Ingredient) in North Carolina. News reports reveal the world-class facility designed to provide diabetes patients with modern treatments is the largest investment in a life sciences facility in the …